Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 536

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Pediatric Pulmonary Hypertension

Open access
Ivy, D. Dunbar, Abman, Steven H., Barst, Robyn J., Berger, Rolf M.F., Bonnet, Damien, Fleming, Thomas R., Haworth, Sheila G., Raj, J. Usha, Rosenzweig, Erika B., Schulze Neick, Ingram, Steinhorn, Robin H., Beghetti, Maurice·2013·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2013.10.028
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2013.10.028

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 99

  1. Haworth, 2009, Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006, Heart, 95, 312, 10.1136/hrt.2008.150086 · DOI · Paper page
  2. Fraisse, 2010, Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France, Arch Cardiovasc Dis, 103, 66, 10.1016/j.acvd.2009.12.001 · doi:10.1016/j.acvd.2009.12.001
  3. Barst, 2012, Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management, Circulation, 125, 113, 10.1161/CIRCULATIONAHA.111.026591 · DOI · Paper page
  4. Berger, 2012, Clinical features of paediatric pulmonary hypertension: a registry study, Lancet, 379, 537, 10.1016/S0140-6736(11)61621-8 · DOI · Paper page
  5. Barst, 2011, Pulmonary arterial hypertension: a comparison between children and adults, Eur Respir J, 37, 665, 10.1183/09031936.00056110 · DOI · Paper page
  6. D’Alonzo, 1991, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 · DOI · Paper page
  7. Atz, 1999, Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing, J Am Coll Cardiol, 33, 813, 10.1016/S0735-1097(98)00668-8 · DOI
  8. Rimensberger, 2001, Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms, Circulation, 103, 544, 10.1161/01.CIR.103.4.544 · DOI · Paper page
  9. Balzer, 2002, Inhaled nitric oxide as a preoperative test (INOP test I): the INOP Test Study Group, Circulation, 106, I76, 10.1161/01.cir.0000032875.55215.cb · DOI
  10. Ivy, 2008, Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension, J Am Coll Cardiol, 51, 161, 10.1016/j.jacc.2007.09.031 · DOI · Paper page
  11. Takatsuki, 2013, Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension, Pediatr Cardiol, 34, 1006, 10.1007/s00246-012-0597-9 · doi:10.1007/s00246-012-0597-9
  12. Yung, 2004, Outcomes in children with idiopathic pulmonary arterial hypertension, Circulation, 110, 660, 10.1161/01.CIR.0000138104.83366.E9 · doi:10.1161/01.cir.0000138104.83366.e9
  13. Sitbon, 2005, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension, Circulation, 111, 3105, 10.1161/CIRCULATIONAHA.104.488486 · DOI · Paper page
  14. Giglia, 2010, Preoperative pulmonary hemodynamics and assessment of operability: is there a pulmonary vascular resistance that precludes cardiac operation?, Pediatric Crit Care Med, 11, S57, 10.1097/PCC.0b013e3181d10cce · doi:10.1097/pcc.0b013e3181d10cce
  15. Moller, 1991, Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960, Am J Cardiol, 68, 1491, 10.1016/0002-9149(91)90284-R · DOI
  16. Douwes, 2011, Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria, Eur Heart J, 32, 3137, 10.1093/eurheartj/ehr282 · DOI
  17. Kawut, 2005, New predictors of outcome in idiopathic pulmonary arterial hypertension, Am J Cardiol, 95, 199, 10.1016/j.amjcard.2004.09.006 · DOI · Paper page
  18. Austin, 2012, Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension, Circ Cardiovasc Genet, 5, 336, 10.1161/CIRCGENETICS.111.961888 · DOI · Paper page
  19. Ma, 2013, A novel channelopathy in pulmonary arterial hypertension, N Engl J Med, 369, 351, 10.1056/NEJMoa1211097 · DOI · Paper page
  20. Kerstjens-Frederikse, 2013, TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension, J Med Genet, 50, 500, 10.1136/jmedgenet-2012-101152 · DOI · Paper page
  21. Adatia, 2009, Pulmonary venous hypertension or pulmonary hypertension due to left heart disease, Prog Pediatr Cardiol, 27, 35, 10.1016/j.ppedcard.2009.09.006 · doi:10.1016/j.ppedcard.2009.09.006
  22. Mourani, 2013, Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond, Curr Opin Pediatr, 25, 329, 10.1097/MOP.0b013e328360a3f6 · DOI
  23. Thebaud, 2009, Pulmonary hypertension associated with congenital diaphragmatic hernia, Cardiol Young, 19, 49, 10.1017/S1047951109003965 · doi:10.1017/s1047951109003965
  24. Rollins, 2012, Recent advances in the management of congenital diaphragmatic hernia, Curr Opin Pediatr, 24, 379, 10.1097/MOP.0b013e328352c4f2 · doi:10.1097/mop.0b013e328352c4f2
  25. Cerro, 2011, A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: report from the PVRI Pediatric Taskforce, Panama 2011, Pulm Circ, 1, 286, 10.4103/2045-8932.83456 · DOI · Paper page
  26. Mitchell, 2004, Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure, J Thorac Cardiovasc Surg, 128, 693, 10.1016/S0022-5223(04)00991-2 · doi:10.1016/s0022-5223(04)00991-2
  27. Takatsuki, 2011, Connective tissue disease presenting with signs and symptoms of pulmonary hypertension in children, Pediatr Cardiol, 32, 828, 10.1007/s00246-011-9950-7 · doi:10.1007/s00246-011-9950-7
  28. Cooney, 1982, Pulmonary hypoplasia in Down’s syndrome, N Engl J Med, 307, 1170, 10.1056/NEJM198211043071902 · DOI · Paper page
  29. Cua, 2011, Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine, Eur J Pediatr, 170, 859, 10.1007/s00431-010-1361-x · DOI
  30. Hawkins, 2011, Management of pulmonary hypertension in Down syndrome, Eur J Pediatr, 170, 915, 10.1007/s00431-010-1378-1 · doi:10.1007/s00431-010-1378-1
  31. van Loon, 2011, Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005, Circulation, 124, 1755, 10.1161/CIRCULATIONAHA.110.969584 · DOI · Paper page
  32. Levy, 2013, Do tertiary paediatric hospitals deal with the same spectrum of paediatric pulmonary hypertension as multicentre registries?, Eur Respir J, 41, 236, 10.1183/09031936.00114212 · doi:10.1183/09031936.00114212
  33. Moledina, 2010, Childhood idiopathic pulmonary arterial hypertension: a national cohort study, Heart, 96, 1401, 10.1136/hrt.2009.182378 · DOI
  34. Sandoval, 1995, Primary pulmonary hypertension in children: clinical characterization and survival, J Am Coll Cardiol, 25, 466, 10.1016/0735-1097(94)00391-3 · doi:10.1016/0735-1097(94)00391-3
  35. van Loon, 2010, Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies, Am J Cardiol, 106, 117, 10.1016/j.amjcard.2010.02.023 · DOI
  36. Manes, 2013, Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups, Eur Heart J
  37. Haworth, 2008, The management of pulmonary hypertension in children, Arch Dis Child, 93, 620, 10.1136/adc.2007.120493 · doi:10.1136/adc.2007.120493
  38. Rosenzweig, 2009, Pulmonary arterial hypertension in children: diagnostic work up and challenges, Prog Pediatr Cardiol, 27, 7, 10.1016/j.ppedcard.2009.09.003 · doi:10.1016/j.ppedcard.2009.09.003
  39. Beghetti, 2013, Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice, Eur Respir J, 42, 689, 10.1183/09031936.00140112 · DOI
  40. Condino, 2005, Portopulmonary hypertension in pediatric patients, J Pediatr, 147, 20, 10.1016/j.jpeds.2005.02.019 · doi:10.1016/j.jpeds.2005.02.019
  41. Lammers, 2011, Functional classification of pulmonary hypertension in children: report from the PVRI Pediatric Taskforce, Panama 2011, Pulm Circ, 1, 280, 10.4103/2045-8932.83445 · doi:10.4103/2045-8932.83445
  42. Ivy, 2010, Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings, Am J Cardiol, 106, 1332, 10.1016/j.amjcard.2010.06.064 · DOI
  43. Bernus, 2009, Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension, Chest, 135, 745, 10.1378/chest.08-0187 · doi:10.1378/chest.08-0187
  44. Lammers, 2009, Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension, Int J Cardiol, 135, 21, 10.1016/j.ijcard.2008.03.009 · DOI
  45. Van Albada, 2008, Biological serum markers in the management of pediatric pulmonary arterial hypertension, Pediatr Res, 63, 321, 10.1203/PDR.0b013e318163a2e7 · DOI
  46. Lammers, 2010, Heart rate variability predicts outcome in children with pulmonary arterial hypertension, Int J Cardiol, 142, 159, 10.1016/j.ijcard.2008.12.087 · DOI
  47. Carmosino, 2007, Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization, Anesth Analg, 104, 521, 10.1213/01.ane.0000255732.16057.1c · doi:10.1213/01.ane.0000255732.16057.1c
  48. Hill, 2010, Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry, Catheter Cardiovasc Interv, 76, 865, 10.1002/ccd.22693 · DOI
  49. Taylor, 2007, Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension, Br J Anaesth, 98, 657, 10.1093/bja/aem059 · doi:10.1093/bja/aem059
  50. Alkon, 2010, Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension, Am J Cardiol, 106, 430, 10.1016/j.amjcard.2010.03.048 · DOI
  51. Kassem, 2013, Prognostic significance of 2-dimensional, M-mode, and Doppler echo indices of right ventricular function in children with pulmonary arterial hypertension, Am Heart J, 165, 1024, 10.1016/j.ahj.2013.02.027 · DOI
  52. Lammers, 2012, Value of tissue Doppler echocardiography in children with pulmonary hypertension, J Am Soc Echocardiogr, 25, 504, 10.1016/j.echo.2012.01.017 · DOI
  53. Takatsuki, 2012, Tissue Doppler imaging predicts adverse outcome in children with idiopathic pulmonary arterial hypertension, J Pediatr, 161, 1126, 10.1016/j.jpeds.2012.05.050 · DOI
  54. Koestenberger, 2009, Right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values, J Am Soc Echocardiogr, 22, 715, 10.1016/j.echo.2009.03.026 · DOI · Paper page
  55. Lammers, 2011, Comparison of 6-min walk test distance and cardiopulmonary exercise test performance in children with pulmonary hypertension, Arch Dis Child, 96, 141, 10.1136/adc.2009.169904 · DOI
  56. Smith, 2009, Safety of maximal cardiopulmonary exercise testing in pediatric patients with pulmonary hypertension, Chest, 135, 1209, 10.1378/chest.08-1658 · DOI
  57. Moledina, 2013, Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension, Circ Cardiovasc Imaging, 6, 407, 10.1161/CIRCIMAGING.112.000082 · DOI
  58. Hunter, 2008, Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension, Am Heart J, 155, 166, 10.1016/j.ahj.2007.08.014 · DOI
  59. Sajan, 2011, Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival, Am Heart J, 162, 562, 10.1016/j.ahj.2011.06.014 · doi:10.1016/j.ahj.2011.06.014
  60. Moledina, 2011, Fractal branching quantifies vascular changes and predicts survival in pulmonary hypertension: a proof of principle study, Heart, 97, 1245, 10.1136/hrt.2010.214130 · doi:10.1136/hrt.2010.214130
  61. Duncan, 2012, Circulating cytokines and growth factors in pediatric pulmonary hypertension, Mediators Inflamm, 2012, 143428, 10.1155/2012/143428 · doi:10.1155/2012/143428
  62. Yeager, 2012, Plasma proteomics of differential outcome to long-term therapy in children with idiopathic pulmonary arterial hypertension, Proteomics Clin Appl, 6, 257, 10.1002/prca.201100078 · DOI
  63. Smadja, 2011, Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension, Angiogenesis, 14, 17, 10.1007/s10456-010-9192-y · DOI
  64. Yeager, 2012, Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension, Chest, 141, 944, 10.1378/chest.11-0205 · DOI
  65. Yeager, 2012, Circulating fibrocytes are increased in children and young adults with pulmonary hypertension, Eur Respir J, 39, 104, 10.1183/09031936.00072311 · DOI
  66. Cabral, 2013, Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment, J Pediatr (Rio J), 89, 226, 10.1016/j.jped.2012.11.009 · doi:10.1016/j.jped.2012.11.009
  67. Lakshminrusimha, 2012, The pulmonary circulation in neonatal respiratory failure, Clin Perinatol, 39, 655, 10.1016/j.clp.2012.06.006 · DOI
  68. McLaughlin, 2009, J Am Coll Cardiol, 53, 1573, 10.1016/j.jacc.2009.01.004 · DOI · Paper page
  69. Barst, 1999, Vasodilator therapy for primary pulmonary hypertension in children, Circulation, 99, 1197, 10.1161/01.CIR.99.9.1197 · DOI · Paper page
  70. Barst, 2003, Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension, Clin Pharmacol Ther, 73, 372, 10.1016/S0009-9236(03)00005-5 · DOI · Paper page
  71. Beghetti, 2009, Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study, Br J Clin Pharmacol, 68, 948, 10.1111/j.1365-2125.2009.03532.x · DOI
  72. Beghetti, 2008, Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance Program, Pediatr Res, 64, 200, 10.1203/PDR.0b013e318179954c · doi:10.1203/pdr.0b013e318179954c
  73. Galie, 2006, Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study, Circulation, 114, 48, 10.1161/CIRCULATIONAHA.106.630715 · DOI · Paper page
  74. Hislop, 2011, Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children, Eur Respir J, 38, 70, 10.1183/09031936.00053510 · doi:10.1183/09031936.00053510
  75. Maiya, 2006, Response to bosentan in children with pulmonary hypertension, Heart, 92, 664, 10.1136/hrt.2005.072314 · doi:10.1136/hrt.2005.072314
  76. Rosenzweig, 2005, Effects of long-term bosentan in children with pulmonary arterial hypertension, J Am Coll Cardiol, 46, 697, 10.1016/j.jacc.2005.01.066 · DOI · Paper page
  77. Takatsuki, 2013, Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension, Pediatr Pulmonol, 48, 27, 10.1002/ppul.22555 · doi:10.1002/ppul.22555
  78. Zuckerman, 2011, Ambrisentan for pulmonary arterial hypertension due to congenital heart disease, Am J Cardiol, 107, 1381, 10.1016/j.amjcard.2010.12.051 · DOI
  79. Abman, 2013, Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension, Am J Respir Crit Care Med, 187, 572, 10.1164/rccm.201210-1928PP · doi:10.1164/rccm.201210-1928pp
  80. Abrams, 2000, Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension, Heart, 84, E4, 10.1136/heart.84.2.e4 · doi:10.1136/heart.84.2.e4
  81. Apitz, 2010, Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension, J Am Coll Cardiol, 55, 1456, 10.1016/j.jacc.2009.11.065 · doi:10.1016/j.jacc.2009.11.065
  82. Barst, 2012, STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive patients with pediatric pulmonary arterial hypertension(abstr), Eur Heart J, 33, 979
  83. Barst, 2012, A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension, Circulation, 125, 324, 10.1161/CIRCULATIONAHA.110.016667 · DOI · Paper page
  84. Humpl, 2011, Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease, Cardiol Young, 21, 187, 10.1017/S1047951110001745 · doi:10.1017/s1047951110001745
  85. Humpl, 2005, Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study, Circulation, 111, 3274, 10.1161/CIRCULATIONAHA.104.473371 · doi:10.1161/circulationaha.104.473371
  86. Rosenzweig, 2010, Tadalafil for the treatment of pulmonary arterial hypertension, Expert Opin Pharmacother, 11, 127, 10.1517/14656560903413542 · DOI
  87. Takatsuki, 2012, Initial experience with tadalafil in pediatric pulmonary arterial hypertension, Pediatr Cardiol, 33, 683, 10.1007/s00246-012-0180-4 · DOI
  88. Limsuwan, 2008, Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease, Int J Cardiol, 129, 333, 10.1016/j.ijcard.2007.08.084 · DOI
  89. Melnick, 2010, Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension, Am J Cardiol, 105, 1485, 10.1016/j.amjcard.2009.12.075 · doi:10.1016/j.amjcard.2009.12.075
  90. Tissot, 2009, Review of inhaled iloprost for the control of pulmonary artery hypertension in children, Vasc Health Risk Manag, 5, 325
  91. Krishnan, 2012, Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children, Am J Cardiol, 110, 1704, 10.1016/j.amjcard.2012.07.037 · doi:10.1016/j.amjcard.2012.07.037
  92. Ivy, 2009, Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension, Infect Control Hosp Epidemiol, 30, 823, 10.1086/605320 · DOI
  93. Lammers, 2007, Epoprostenol treatment in children with severe pulmonary hypertension, Heart, 93, 739, 10.1136/hrt.2006.096412 · DOI
  94. Rosenzweig, 1999, Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects, Circulation, 99, 1858, 10.1161/01.CIR.99.14.1858 · DOI · Paper page
  95. Siehr, 2013, Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics, J Heart Lung Transplant, 32, 546, 10.1016/j.healun.2013.01.1055 · doi:10.1016/j.healun.2013.01.1055
  96. Doran, 2008, Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension, Int J Clin Pract Suppl, 5, 10.1111/j.1742-1241.2008.01811.x · DOI
  97. Levy, 2011, Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension, J Pediatr, 158, 584, 10.1016/j.jpeds.2010.09.025 · DOI
  98. Sandoval, 1998, Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment, J Am Coll Cardiol, 32, 297, 10.1016/S0735-1097(98)00238-1 · DOI · Paper page
  99. Baruteau, 2012, Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results, Ann Thorac Surg, 94, 817, 10.1016/j.athoracsur.2012.03.099 · DOI

Cited by

See all 536

Metadata

Authors
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze Neick, I., Steinhorn, R. H., & Beghetti, M.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2013-12
Volume
62
Issue
25
Pages
D117-D126
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2013.10.028
OpenAlex
W2144118419
Cited by
536
References
12
FWCI
36.05
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pediatric Pulmonary Hypertension. https://app.cochat.ai/papers/10.1016/j.jacc.2013.10.028
The paper
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze Neick, I., Steinhorn, R. H., & Beghetti, M. (2013). Pediatric Pulmonary Hypertension. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2013.10.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.